BioDlink International Company Limited (1875), Wuxi Biologics, and the Offeror Issue Clarification on Share Options Under Rule 3.8

Bulletin Express

03/03

BioDlink International Company Limited (1875), the Offeror, and Wuxi Biologics jointly referenced their previous announcements dated 14 January 2026, 12 February 2026, and 1 March 2026 regarding the Offers and related matters under the Takeovers Code. According to the announcement, after the vesting of 0.14 million Share Options on 1 March 2026, there are 7.63 million outstanding Share Options in total, comprising 7.49 million vested unexercised options and 0.14 million unvested options.

The clarification indicates that all other information and content presented in the 1 March 2026 announcement remain unchanged. The company reiterates that the clarification is supplemental and should be read alongside the previously issued announcement pursuant to Rule 3.8 of the Takeovers Code.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1144819988"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1144819988\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1144819988?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-03 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144819988","market":"hk","top_or_hot":-1,"title":"BioDlink International Company Limited (1875), Wuxi Biologics, and the Offeror Issue Clarification on Share Options Under Rule 3.8","media":"Bulletin Express","content":"<p>BioDlink International Company Limited (1875), the Offeror, and Wuxi Biologics jointly referenced their previous announcements dated 14 January 2026, 12 February 2026, and 1 March 2026 regarding the Offers and related matters under the Takeovers Code. According to the announcement, after the vesting of 0.14 million Share Options on 1 March 2026, there are 7.63 million outstanding Share Options in total, comprising 7.49 million vested unexercised options and 0.14 million unvested options.</p>\n<p>The clarification indicates that all other information and content presented in the 1 March 2026 announcement remain unchanged. The company reiterates that the clarification is supplemental and should be read alongside the previously issued announcement pursuant to Rule 3.8 of the Takeovers Code.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioDlink International Company Limited (1875), Wuxi Biologics, and the Offeror Issue Clarification on Share Options Under Rule 3.8</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioDlink International Company Limited (1875), Wuxi Biologics, and the Offeror Issue Clarification on Share Options Under Rule 3.8\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-03-03 20:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>BioDlink International Company Limited (1875), the Offeror, and Wuxi Biologics jointly referenced their previous announcements dated 14 January 2026, 12 February 2026, and 1 March 2026 regarding the Offers and related matters under the Takeovers Code. According to the announcement, after the vesting of 0.14 million Share Options on 1 March 2026, there are 7.63 million outstanding Share Options in total, comprising 7.49 million vested unexercised options and 0.14 million unvested options.</p>\n<p>The clarification indicates that all other information and content presented in the 1 March 2026 announcement remain unchanged. The company reiterates that the clarification is supplemental and should be read alongside the previously issued announcement pursuant to Rule 3.8 of the Takeovers Code.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01875","symbol_name":"東曜藥業-B","start_time":0,"source_url":"","article_id":"1144819988","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144819988","pubTimestamp":1772539511,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"BioDlink International Company Limited (1875), the Offeror, and Wuxi Biologics jointly referenced their previous announcements dated 14 January 2026, 12 February 2026, and 1 March 2026 regarding the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01875":"东曜药业-B"},"translate_title":"BioDlink International Company Limited(1875)、药明生物及要约人根据第3.8条就购股权作出澄清","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01875":1},"content_text":"BioDlink International Company Limited (1875), the Offeror, and Wuxi Biologics jointly referenced their previous announcements dated 14 January 2026, 12 February 2026, and 1 March 2026 regarding the Offers and related matters under the Takeovers Code. According to the announcement, after the vesting of 0.14 million Share Options on 1 March 2026, there are 7.63 million outstanding Share Options in total, comprising 7.49 million vested unexercised options and 0.14 million unvested options.\nThe clarification indicates that all other information and content presented in the 1 March 2026 announcement remain unchanged. The company reiterates that the clarification is supplemental and should be read alongside the previously issued announcement pursuant to Rule 3.8 of the Takeovers Code.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}